Last 7 days
1.3%
Last 30 days
-4.5%
Last 90 days
-12.4%
Trailing 12 Months
-13.3%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MDT | 105.5B | 30.8B | -7.09% | -24.59% | 25.94 | 3.43 | -3.19% | -17.38% |
SYK | 104.1B | 18.4B | 2.26% | 8.00% | 44.16 | 5.64 | 7.84% | 18.25% |
ISRG | 84.2B | 6.2B | -4.47% | -13.27% | 63.66 | 13.53 | 8.97% | -22.43% |
BDX | 67.4B | 19.0B | -5.16% | -6.78% | 41.86 | 3.55 | -0.43% | -8.78% |
EW | 49.8B | 5.4B | 2.41% | -25.12% | 32.74 | 9.26 | 2.86% | 1.25% |
MID-CAP | ||||||||
SWAV | 7.2T | 489.7M | 9.34% | 31.15% | 82.2K | 16.8K | 106.51% | 2464.23% |
PEN | 10.2B | 847.1M | -3.64% | 34.52% | -5.1K | 12.05 | 13.32% | -137.89% |
GMED | 5.2B | 1.0B | -11.64% | -20.31% | 30.19 | 5.09 | 6.76% | 24.45% |
IRTC | 3.5B | 410.9M | 4.51% | -3.13% | -29.82 | 8.43 | 27.29% | -14.60% |
TNDM | 2.7B | 801.2M | 1.13% | -58.87% | -28.25 | 3.34 | 14.00% | -707.69% |
SMALL-CAP | ||||||||
SILK | 1.7B | 138.6M | -15.68% | 29.18% | -30.43 | 12.07 | 36.62% | -10.44% |
AVNS | 1.3B | 820.0M | -8.35% | -12.22% | 25.89 | 1.59 | 10.13% | 701.59% |
BLFS | 853.3M | 154.8M | -6.04% | 0.61% | -8.2 | 5.51 | 60.29% | -2309.58% |
CSII | 828.4M | 239.8M | 0.30% | 1.49% | -21.88 | 3.45 | -4.74% | -31.15% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 1.7% | 6,222 | 6,118 | 5,964 | 5,906 | 5,710 |
Gross Profit | 1.2% | 4,196 | 4,146 | 4,065 | 4,066 | 3,959 |
Operating Expenses | 5.1% | 2,619 | 2,491 | 2,367 | 2,253 | 2,138 |
S&GA Expenses | 4.0% | 1,740 | 1,673 | 1,600 | 1,532 | 1,467 |
R&D Expenses | 7.4% | 879 | 818 | 767 | 722 | 671 |
EBITDA | -3.6% | 1,607 | 1,666 | 1,725 | 2,124 | - |
EBITDA Margin | -5.2% | 0.26* | 0.27* | 0.34* | 0.36* | - |
Earnings Before Taxes | -3.6% | 1,607 | 1,666 | 1,725 | 1,844 | 1,890 |
EBT Margin | -5.2% | 0.26* | 0.27* | 0.34* | 0.31* | - |
Net Income | -4.0% | 1,322 | 1,378 | 1,435 | 1,644 | 1,705 |
Net Income Margin | -5.7% | 0.21* | 0.23* | 0.29* | 0.28* | - |
Free Cahsflow | -8.0% | 1,491 | 1,621 | 1,739 | 1,835 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | -2.2% | 12,974 | 13,261 | 13,705 | 13,678 | 13,555 |
Current Assets | -0.6% | 6,253 | 6,293 | 6,293 | 5,803 | 5,845 |
Cash Equivalents | 2.8% | 1,581 | 1,538 | 1,536 | 1,103 | 1,291 |
Inventory | 6.7% | 893 | 837 | 724 | 653 | 587 |
Net PPE | 5.8% | 2,374 | 2,244 | 2,109 | 1,968 | 1,876 |
Goodwill | 0.1% | 349 | 348 | 349 | 343 | 344 |
Liabilities | 10.4% | 1,861 | 1,687 | 1,623 | 1,522 | 1,604 |
Current Liabilities | 15.3% | 1,422 | 1,233 | 1,175 | 1,112 | 1,150 |
Shareholder's Equity | -4.1% | 11,042 | 11,515 | 12,082 | 12,157 | 11,901 |
Retained Earnings | -12.9% | 3,500 | 4,018 | 4,683 | 4,858 | 4,761 |
Additional Paid-In Capital | 0.2% | 7,704 | 7,685 | 7,484 | 7,355 | 7,164 |
Accumulated Depreciation | 27.8% | 1,238 | 969 | - | - | - |
Shares Outstanding | -0.9% | 350 | 353 | 357 | 359 | 358 |
Minority Interest | 20.6% | 71.00 | 59.00 | 59.00 | 55.00 | 50.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -8.0% | 1,491 | 1,621 | 1,739 | 1,835 | 2,089 |
Share Based Compensation | 1.9% | 513 | 503 | 485 | 467 | 449 |
Cashflow From Investing | 784.4% | 1,371 | 155 | -1,228 | -2,079 | -2,461 |
Cashflow From Financing | -61.8% | -2,572 | -1,590 | -595 | -54.70 | 43.00 |
Buy Backs | 62.3% | 2,607 | 1,607 | 607 | 107 | 0.00 |
68.5%
36.9%
16.9%
Y-axis is the maximum loss one would have experienced if Intuitive Surgical was unfortunately bought at previous high price.
16.5%
20.0%
10.0%
14.3%
FIve years rolling returns for Intuitive Surgical.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -5.37 | 534,326 | 2,108,330 | 0.06% |
2023-03-10 | BAILLIE GIFFORD & CO | added | 1.66 | 345,654,000 | 1,132,740,000 | 1.18% |
2023-03-10 | Financial Alternatives, Inc | new | - | 315,236 | 315,236 | 0.31% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 18.57 | 31,999,400 | 79,154,400 | 0.09% |
2023-03-10 | MATHER GROUP, LLC. | reduced | -12.91 | 55,335 | 295,335 | 0.01% |
2023-03-08 | Capital Asset Advisory Services LLC | added | 18.33 | 508,674 | 1,234,670 | 0.10% |
2023-03-06 | NORTH STAR ASSET MANAGEMENT INC | added | 10.04 | 1,892,380 | 5,283,380 | 0.33% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 1.32 | 10,519,000 | 34,738,000 | 0.17% |
2023-03-03 | TIAA, FSB | reduced | -3.54 | 174,434 | 651,434 | -% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 2,442,550 | 2,442,550 | 0.03% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | price t rowe associates inc /md/ | 5.9% | 20,823,995 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 8.33% | 29,425,186 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 8.0% | 28,447,145 | SC 13G/A | |
Feb 14, 2022 | price t rowe associates inc /md/ | 6.9% | 24,756,021 | SC 13G/A | |
Feb 07, 2022 | blackrock inc. | 7.4% | 26,538,660 | SC 13G/A | |
Feb 16, 2021 | price t rowe associates inc /md/ | 8.1% | 9,599,898 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 7.76% | 9,127,891 | SC 13G/A | |
Feb 08, 2021 | fmr llc | - | 0 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 7.6% | 8,888,304 | SC 13G/A | |
Feb 14, 2020 | price t rowe associates inc /md/ | 8.9% | 10,347,449 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 89.83 -62.65% | 115.43 -52.00% | 160.35 -33.33% | 205.33 -14.62% | 234.58 -2.46% |
Current Inflation | 82.50 -65.70% | 104.30 -56.63% | 141.86 -41.01% | 179.18 -25.50% | 203.67 -15.31% |
Very High Inflation | 73.50 -69.44% | 90.90 -62.20% | 120.15 -50.04% | 148.97 -38.06% | 168.15 -30.08% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 10, 2023 | DEF 14A | DEF 14A | |
Mar 10, 2023 | DEFA14A | DEFA14A | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-01 | Curet Myriam | sold | -286,273 | 228 | -1,253 | evp & chief medical officer |
2023-02-28 | Widman Fredrik | sold (taxes) | -104,602 | 229 | -456 | vp corporate controller |
2023-02-28 | Curet Myriam | sold (taxes) | -344,314 | 229 | -1,501 | evp & chief medical officer |
2023-02-28 | GUTHART GARY S | acquired | - | - | 6,371 | president & ceo |
2023-02-28 | DeSantis Robert | acquired | - | - | 3,679 | evp & chief product officer |
2023-02-28 | MOHR MARSHALL | acquired | - | - | 3,259 | executive vp global business s |
2023-02-28 | Samath Jamie | sold (taxes) | -159,655 | 229 | -696 | chief financial officer |
2023-02-28 | Charlton Henry L | sold (taxes) | -170,666 | 229 | -744 | senior vice president & chief |
2023-02-28 | Rosa David J. | acquired | - | - | 3,760 | evp chief strategy & growth of |
2023-02-28 | Samath Jamie | acquired | - | - | 2,009 | chief financial officer |
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue: | ||||
Total revenue | $ 1,557.4 | $ 1,403.3 | $ 4,567.2 | $ 4,159.4 |
Cost of revenue: | ||||
Total cost of revenue | 505.3 | 431.9 | 1,482.1 | 1,261.7 |
Gross profit | 1,052.1 | 971.4 | 3,085.1 | 2,897.7 |
Operating expenses: | ||||
Selling, general and administrative | 436.1 | 363.3 | 1,245.6 | 1,039.5 |
Research and development | 217.1 | 165.5 | 634.9 | 487.6 |
Total operating expenses | 653.2 | 528.8 | 1,880.5 | 1,527.1 |
Income from operations | 398.9 | 442.6 | 1,204.6 | 1,370.6 |
Interest and other income, net | 3.9 | 18.5 | 7.5 | 65.5 |
Income before taxes | 402.8 | 461.1 | 1,212.1 | 1,436.1 |
Income tax expense | 78.1 | 73.9 | 204.4 | 90.7 |
Net income | 324.7 | 387.2 | 1,007.7 | 1,345.4 |
Less: net income attributable to noncontrolling interest in joint venture | 0.7 | 6.7 | 10.3 | 21.4 |
Net income attributable to Intuitive Surgical, Inc. | $ 324.0 | $ 380.5 | $ 997.4 | $ 1,324.0 |
Net income per share attributable to Intuitive Surgical, Inc.: | ||||
Basic (in dollars per share) | $ 0.91 | $ 1.07 | $ 2.79 | $ 3.72 |
Diluted (in dollars per share) | $ 0.90 | $ 1.04 | $ 2.74 | $ 3.63 |
Shares used in computing net income per share attributable to Intuitive Surgical, Inc.: | ||||
Basic (in shares) | 355.3 | 356.8 | 357.2 | 355.6 |
Diluted (in shares) | 360.5 | 366.8 | 363.7 | 365.1 |
Other comprehensive loss, net of tax: | ||||
Change in unrealized gains on hedge instruments | $ 2.3 | $ 2.0 | $ 7.7 | $ 8.0 |
Change in unrealized losses on available-for-sale securities | (37.3) | (4.5) | (161.4) | (20.5) |
Change in foreign currency translation losses | (10.0) | (2.8) | (12.0) | (7.9) |
Change in prior service cost for employee benefit plans | 0.1 | 0.2 | 0.2 | 0.4 |
Other comprehensive loss | (44.9) | (5.1) | (165.5) | (20.0) |
Total comprehensive income | 279.8 | 382.1 | 842.2 | 1,325.4 |
Less: comprehensive income (loss) attributable to noncontrolling interest | (0.8) | 6.6 | 8.2 | 21.0 |
Total comprehensive income attributable to Intuitive Surgical, Inc. | 280.6 | 375.5 | 834.0 | 1,304.4 |
Corporate Joint Venture | ||||
Operating expenses: | ||||
Less: net income attributable to noncontrolling interest in joint venture | 0.7 | 6.7 | 10.3 | 21.4 |
Product | ||||
Revenue: | ||||
Total revenue | 1,297.5 | 1,170.6 | 3,806.3 | 3,481.2 |
Cost of revenue: | ||||
Total cost of revenue | 421.6 | 355.8 | 1,239.9 | 1,049.1 |
Service | ||||
Revenue: | ||||
Total revenue | 259.9 | 232.7 | 760.9 | 678.2 |
Cost of revenue: | ||||
Total cost of revenue | $ 83.7 | $ 76.1 | $ 242.2 | $ 212.6 |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 1,538.0 | $ 1,290.9 |
Short-term investments | 2,775.9 | 2,913.1 |
Accounts receivable, net | 849.6 | 782.7 |
Inventory | 837.1 | 587.1 |
Prepaids and other current assets | 292.5 | 271.1 |
Total current assets | 6,293.1 | 5,844.9 |
Property, plant, and equipment, net | 2,243.7 | 1,876.4 |
Long-term investments | 3,078.1 | 4,415.5 |
Deferred tax assets | 587.4 | 441.4 |
Intangible and other assets, net | 710.3 | 633.2 |
Goodwill | 348.2 | 343.6 |
Total assets | 13,260.8 | 13,555.0 |
Current liabilities: | ||
Accounts payable | 164.2 | 121.2 |
Accrued compensation and employee benefits | 308.2 | 350.1 |
Deferred revenue | 358.9 | 377.2 |
Other accrued liabilities | 402.1 | 301.3 |
Total current liabilities | 1,233.4 | 1,149.8 |
Other long-term liabilities | 453.4 | 453.7 |
Total liabilities | 1,686.8 | 1,603.5 |
Contingencies (Note 8) | ||
Stockholders’ equity: | ||
Preferred stock, 2.5 shares authorized, $0.001 par value, issuable in series; zero shares issued and outstanding as of September 30, 2022, and December 31, 2021 | 0.0 | 0.0 |
Common stock, 600.0 shares authorized, $0.001 par value, 353.3 shares and 357.7 shares issued and outstanding as of September 30, 2022, and December 31, 2021, respectively | 0.4 | 0.4 |
Additional paid-in capital | 7,684.8 | 7,164.0 |
Retained earnings | 4,017.8 | 4,760.9 |
Accumulated other comprehensive loss | (187.6) | (24.2) |
Total Intuitive Surgical, Inc. stockholders’ equity | 11,515.4 | 11,901.1 |
Noncontrolling interest in joint venture | 58.6 | 50.4 |
Total stockholders’ equity | 11,574.0 | 11,951.5 |
Total liabilities and stockholders’ equity | $ 13,260.8 | $ 13,555.0 |